Aroa Biosurgery Symphony Trial Meets Primary Endpoint in Diabetic Wound Study
Aroa Biosurgery confirms Symphony randomised controlled trial met primary endpoint
Aroa Biosurgery (ASX: ARX) has announced the completion of its Symphony randomised controlled trial (RCT), with preliminary findings indicating the study achieved its primary endpoint. The Aroa Biosurgery Symphony trial results represent a significant clinical milestone for the company’s CAMP product targeting hard-to-heal diabetic foot ulcers.
The multi-centre US trial compared Symphony against standard of care in treating chronic Wagner grade 1 and 2 diabetic foot ulcers (DFUs) over a 12-week treatment period. The primary endpoint assessed whether more DFUs healed within 12 weeks when treated with Symphony versus standard of care dressings.
Up to 150 patients were enrolled across multiple US sites in this prospective, randomised study. Patients received either Symphony or standard of care dressings weekly until wound healing occurred, or for up to 12 weeks.
Randomised controlled trials represent the gold standard of clinical evidence in medical research. For medical device companies targeting US commercialisation, RCT completion often marks an inflection point, unlocking pathways to reimbursement and formulary inclusion that smaller observational studies cannot achieve.
Brian Ward, CEO
“Randomised controlled trials are regarded as the most robust form of clinical evidence, and these results clearly validate Symphony’s clinical value. We are encouraged by the early study read-out and look forward to publication of the full study results in the coming months.”
When big ASX news breaks, our subscribers know first
What is a randomised controlled trial and why does it matter?
A randomised controlled trial is a clinical study design in which participants are randomly assigned to either a treatment group or a control group. This random assignment eliminates selection bias and ensures any observed differences in outcomes can be attributed to the treatment itself rather than patient characteristics or researcher preference.
RCTs sit at the top of the clinical evidence hierarchy. They provide more reliable data than case studies or observational research because the randomisation process creates comparable groups, allowing researchers to isolate the treatment’s true effect.
For medical device companies operating in the US market, robust RCT data increasingly represents a commercial prerequisite rather than a competitive advantage. US payers, including the Centers for Medicare & Medicaid Services (CMS), have signalled stricter evidence requirements for coverage decisions. Private insurers frequently follow CMS guidance, meaning RCT completion can determine whether a product gains market access or remains restricted to niche applications.
The hierarchy of clinical evidence follows this structure:
- Case studies and case series (lowest evidence tier)
- Observational studies and cohort analyses
- Randomised controlled trials
- Systematic reviews and meta-analyses (highest evidence tier)
Symphony’s RCT positions the product at tier three, providing the level of evidence required to support reimbursement applications and clinical adoption in hospital formularies.
Symphony targets a significant unmet need in diabetic wound care
Symphony is Aroa Biosurgery’s Cellular, Acellular and Matrix-like Product (CAMP), classified as a skin substitute under US regulatory frameworks. The product combines multiple layers of AROA ECM™, a proprietary extracellular matrix bioscaffold derived from ovine forestomach, with high molecular weight hyaluronic acid.
The product is designed specifically for hard-to-heal chronic wounds, including diabetic foot ulcers and venous leg ulcers. In this trial, Symphony targeted Wagner grade 1 and 2 diabetic foot ulcers, a classification system used to assess wound severity. Grade 1 ulcers involve superficial wounds without penetration to deeper structures, while grade 2 ulcers extend to ligaments, tendons, or joint capsules.
Diabetic foot ulcers affect millions of individuals globally and carry significant amputation risk if healing does not occur. Chronic wounds in this patient population often fail to respond to standard wound care protocols, creating demand for advanced tissue regeneration products that can accelerate healing.
Over 7 million AROA devices have been used globally across various procedures to date. The company distributes products into the US market via its direct sales force and through its partnership with TELABio, Inc.
| Feature | Detail |
|---|---|
| Product Type | CAMP / Skin Substitute |
| Core Technology | AROA ECM™ + Hyaluronic Acid |
| Target Wounds | DFUs, Venous Leg Ulcers |
| Application Protocol | Weekly until healing or 12 weeks |
| Trial Design | Multi-centre RCT vs Standard of Care |
Reimbursement pathway strengthened by trial completion
Aroa Biosurgery expects the full publication of Symphony’s RCT results will meet the rigorous clinical evidence thresholds likely to be required under future US reimbursement policy. The company anticipates this data will support both clinical adoption and reimbursement positioning as payers tighten evidence requirements for advanced wound care products.
US reimbursement represents the critical commercial unlock for skin substitute products. CMS has signalled it will apply stricter scrutiny to coverage decisions for tissue-engineered products, meaning companies without robust RCT data face significant barriers to formulary inclusion. Symphony is now positioned ahead of this regulatory shift, with trial data that addresses the evidence gaps payers have identified.
Final analysis and publication of the complete study results remain pending. Once peer-reviewed publication occurs, the data will provide full transparency on healing rates, adverse events, and secondary endpoints, supporting commercial conversations with hospital systems and payer organisations.
The next major ASX story will hit our subscribers first
What comes next for Aroa Biosurgery
Full publication of the Symphony RCT results is expected in the coming months. The peer-reviewed publication will detail complete healing rates, safety profiles, and subgroup analyses, providing the clinical community with comprehensive data to support treatment decisions.
The published results are intended to support Symphony’s clinical adoption in chronic, complex wounds, a category that includes diabetic foot ulcers and venous leg ulcers. Aroa Biosurgery continues to advance US market development through its direct sales force and its partnership with TELABio for broader distribution.
Key next steps include:
- Final statistical analysis of RCT data
- Peer-reviewed publication of full study results
- Continued clinical and commercial rollout in the US market
- Submission of RCT data to US payers for reimbursement consideration
The timeline from RCT completion to publication typically spans three to six months. Investors should monitor for the peer-reviewed publication as the next material catalyst, which will provide full data transparency and enable evidence-based discussions with US payers and hospital formularies.
Aroa Biosurgery is a soft-tissue regeneration company committed to unlocking regenerative healing for complex wounds and soft tissue reconstruction. Founded in 2008 and headquartered in Auckland, New Zealand, the company is listed on the Australian Securities Exchange under ticker ARX.
Want the Next Biotech Breakthrough in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to get market-moving biotech announcements the moment they drop, with expert coverage already done for you.